Application of immunotherapy in malignant pleural mesothelioma
- VernacularTitle:免疫治疗在恶性胸膜间皮瘤中的应用
- Author:
Xiang CHEN
1
;
Yajie ZHANG
1
;
Hecheng LI
1
Author Information
1. Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P. R. China
- Publication Type:Journal Article
- Keywords:
Malignant pleural mesothelioma;
immunotherapy;
clinical trails;
review
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2022;29(07):935-938
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, immune checkpoint inhibitor therapy has changed the treatment of various malignant tumors. Immunotherapy for specific targets currently plays an important role in melanoma, lung cancer and other tumors. Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor. Although the treatments include surgery, chemotherapy and radiotherapy, the clinical efficacy is limited, and the prognosis of advanced patients is poor. With the application of monoclonal antibodies such as programmed death 1/programmed death ligand 1 and cytotoxic T-lymphocyte antigen 4, MPM patients have more treatment options. And compared with traditional chemotherapy, immunotherapy may have the effect of improving survival and shrinking tumors. This article will summarize the current clinical trials of immunotherapy in MPM, and explain the current application and progress of immunotherapy in MPM from both single-agent immunotherapy and combined immunotherapy.
